Literature DB >> 21747092

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Vincenzo Valentini1, Ruud G P M van Stiphout, Guido Lammering, Maria Antonietta Gambacorta, Maria Cristina Barba, Marek Bebenek, Franck Bonnetain, Jean-Francois Bosset, Krzysztof Bujko, Luca Cionini, Jean-Pierre Gerard, Claus Rödel, Aldo Sainato, Rolf Sauer, Bruce D Minsky, Laurence Collette, Philippe Lambin.   

Abstract

PURPOSE: The purpose of this study was to develop accurate models and nomograms to predict local recurrence, distant metastases, and survival for patients with locally advanced rectal cancer treated with long-course chemoradiotherapy (CRT) followed by surgery and to allow for a selection of patients who may benefit most from postoperative adjuvant chemotherapy and close follow-up. PATIENTS AND METHODS: All data (N = 2,795) from five major European clinical trials for rectal cancer were pooled and used to perform an extensive survival analysis and to develop multivariate nomograms based on Cox regression. Data from one trial was used as an external validation set. The variables used in the analysis were sex, age, clinical tumor stage stage, tumor location, radiotherapy dose, concurrent and adjuvant chemotherapy, surgery procedure, and pTNM stage. Model performance was evaluated by the concordance index (c-index). Risk group stratification was proposed for the nomograms.
RESULTS: The nomograms are able to predict events with a c-index for external validation of local recurrence (LR; 0.68), distant metastases (DM; 0.73), and overall survival (OS; 0.70). Pathologic staging is essential for accurate prediction of long-term outcome. Both preoperative CRT and adjuvant chemotherapy have an added value when predicting LR, DM, and OS rates. The stratification in risk groups allows significant distinction between Kaplan-Meier curves for outcome.
CONCLUSION: The easy-to-use nomograms can predict LR, DM, and OS over a 5-year period after surgery. They may be used as decision support tools in future trials by using the three defined risk groups to select patients for postoperative chemotherapy and close follow-up (http://www.predictcancer.org).

Entities:  

Mesh:

Year:  2011        PMID: 21747092     DOI: 10.1200/JCO.2010.33.1595

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  169 in total

Review 1.  Adjuvant chemotherapy for rectal cancer: Is it needed?

Authors:  Kristijonas Milinis; Michael Thornton; Amir Montazeri; Paul S Rooney
Journal:  World J Clin Oncol       Date:  2015-12-10

Review 2.  Role of BAX for outcome prediction in gastrointestinal malignancies.

Authors:  Filippo Pietrantonio; Pamela Biondani; Elisa Ciurlia; Giuseppe Fanetti; Anna Tessari; Gaia Bertarelli; Ilaria Bossi; Valeria Musella; Flavia Melotti; Maria Di Bartolomeo; Francesca Valvo; Alessandro Pellegrinelli; Massimo Milione; Federica Perrone; Filippo de Braud
Journal:  Med Oncol       Date:  2013-05-23       Impact factor: 3.064

3.  [Optimal timing of surgery for rectal cancer after neoadjuvant chemoradiotherapy: which patients would benefit from waiting?].

Authors:  C Petersen
Journal:  Strahlenther Onkol       Date:  2013-10       Impact factor: 3.621

4.  Evidence based radiation oncology with existing technology.

Authors:  Nicolas Isa
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-14

5.  Oncologic results and prognostic predictors of patients with locally advanced rectal cancer showing ypN0 after radical surgery following neoadjuvant chemoradiotherapy.

Authors:  Kyung-Ha Lee; Jae-Chan Kim; Ji-Yeon Kim; Jin-Su Kim
Journal:  Int J Colorectal Dis       Date:  2015-05-23       Impact factor: 2.571

6.  Human cytomegalovirus and Epstein-Barr virus infection impact on (18)F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy.

Authors:  Claudio V Sole; Felipe A Calvo; Carlos Ferrer; Emilio Alvarez; Jose L Carreras; Enrique Ochoa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-01       Impact factor: 9.236

7.  A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032).

Authors:  Michael S Kent; Sumithra J Mandrekar; Rodney Landreneau; Francis Nichols; Nathan R Foster; Thomas A DiPetrillo; Bryan Meyers; Dwight E Heron; David R Jones; Angelina D Tan; Sandra Starnes; Joe B Putnam; Hiran C Fernando
Journal:  Ann Thorac Surg       Date:  2016-04-19       Impact factor: 4.330

8.  ¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.

Authors:  Felipe A Calvo; Claudio V Sole; Dolores de la Mata; Luis Cabezón; Marina Gómez-Espí; Emilio Alvarez; Paz Madariaga; José L Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-23       Impact factor: 9.236

Review 9.  Personalized radiotherapy: concepts, biomarkers and trial design.

Authors:  A H Ree; K R Redalen
Journal:  Br J Radiol       Date:  2015-05-20       Impact factor: 3.039

Review 10.  Controversies in the multimodality management of locally advanced rectal cancer.

Authors:  Robert Díaz Beveridge; Dilara Akhoundova; Gema Bruixola; Jorge Aparicio
Journal:  Med Oncol       Date:  2017-04-24       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.